Rob Volansky

The FDA approved Lytenava for the treatment of neovascular age-related macular degeneration, according to a press release from Outlook Therapeutics.The approval of Lytenava is marks the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.

New EULAR recommendations for the management of rheumatoid arthritis stress that disease-modifying antirheumatic drugs should not be discontinued, even in patients who achieve sustained remission, as flares may occur in those who do.Although there are few significant changes from the previous 2022 recommendations, coauthors Josef Smolen, MD, emeritus professor of medicine at the Medical

DESTIN, Fla. — Osteoarthritis, far from being “simply wear and tear,” demands a multifaceted management strategy, according to a speaker at the Congress of Clinical Rheumatology East.“Rheumatologists tend to be discouraged when thinking about osteoarthritis,” said Amanda E. Nelson, MD, MSCR, RhMSUS, director of the Core Center for Clinical Research at the University

The FDA has granted fast track designation to 4P004, an intra-articular GLP-1 agonist analog, for the treatment of knee osteoarthritis, according to a press release from biotechnology company 4Moving Biotech. The agent, which the company is billing as a potential first-in-class disease-modifying osteoarthritis drug, is engineered for intra-articular administration in patients with synovitis who

Although experts generally support the stated goals of programs targeting rural areas in HHS Secretary Robert F. Kennedy Jr.’s “Make America Healthy Again” initiative, many have questioned whether the actual policies are up to the task.“Overall, the growing attention on rural health care and the barriers faced by rural residents is music to our ears,” Rebecca J.

DESTIN, Fla. — Combination therapy with multiple biologics may be on the horizon for patients with psoriatic arthritis, according to a presenter at the Congress of Clinical Rheumatology East.“We are doing way better with psoriatic arthritis,” said Arthur Kavanaugh, MD, a rheumatologist and professor of medicine at the University of California San Diego. “We really want

Treatment with ixekizumab plus tirzepatide achieves greater disease control, physical function and weight loss vs. monotherapy in patients with psoriatic arthritis and obesity, according to data published in Arthritis & Rheumatology. “Overweight or obesity is disproportionately prevalent in PsA compared with the general population, with estimates ranging from 72% to 82%,” Joseph F. Merola,

A common gut bacterium may be implicated in lupus kidney disease, and could potentially alter the diagnosis and treatment of lupus nephritis going forward, according to findings published in the Annals of the Rheumatic Diseases.“The theory is that the kidney disease in many patients is driven by a single bacteria,” Gregg Silverman, MD, of the New York University Grossman School of

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.“It is quite important and very welcome that the FDA has publicly published their perspective on these therapies in our space of autoimmune and rheumatic conditions,” Leonard H. Calabrese,

Treatment with biologic or targeted synthetic disease-modifying antirheumatic drugs failed to mitigate bone mineral density loss in rheumatoid arthritis, according to data published in Arthritis & Rheumatology.“Because inflammation is considered one of the multiple causes of systemic osteoporosis in RA, it has been hypothesized that suppressing inflammation with [biologic/targeted